Sermorelin + Ipamorelin Research Blend GHRH 1-29 + GHS-R1a Agonist · Physiological GH Axis Research · ≥99% HPLC · Janoshik COA
Sermorelin (GHRH 1-29) and Ipamorelin represent the most physiologically relevant GH axis research combination for somatropause research. Unlike CJC-1295 DAC, Sermorelin has a short half-life (~10-20 minutes) that closely mirrors native GHRH pulsatility. Combined with Ipamorelin’s selective GHS-R1a activation, this blend is studied for restoration of physiological GH pulse patterns in aging models. QSC supplies both at ≥99% HPLC with Janoshik independent COA.
What is the Sermorelin + Ipamorelin research combination?
Sermorelin (GHRH 1-29) + Ipamorelin combines pulsatile GHRH-R stimulation with selective GHS-R1a activation. Sermorelin’s short half-life preserves physiological GH pulsatility architecture; Ipamorelin adds ghrelin receptor activation without cortisol or prolactin elevation. This is studied as the most physiologically authentic dual-pathway GH axis research protocol for somatropause models.
How is Sermorelin + Ipamorelin different from CJC-1295 + Ipamorelin?
Sermorelin has a short half-life (~10-20 min) similar to native GHRH — preserving pulsatility. CJC-1295 with DAC has a 6-8 day half-life via albumin binding — sustained GH elevation. Sermorelin + Ipamorelin is used when pulsatile, physiologically authentic GH patterns are the research goal. CJC-1295 + Ipamorelin is used when sustained GH elevation is the research variable.
Where can I buy Sermorelin and Ipamorelin for research?
QSC stocks both Sermorelin (GHRH 1-29) and Ipamorelin at ≥99% HPLC with Janoshik independent COA verifiable at verify.janoshik.com. Sold separately. Research use only.
Buy Sermorelin + Ipamorelin Research Blend Components
Both compounds available at ≥99% HPLC · Janoshik Independent COA · verify.janoshik.com
Research Use Only: All QSC products sold strictly for in vitro laboratory research. Not for human or veterinary use. Information on this page is educational and does not constitute medical advice.
